SIRGs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinoma.

ABSTRACT:

Background

Esophagogastric junction adenocarcinoma (EGJA) is a special malignant tumor with unknown biological behavior. PD-1 checkpoint inhibitors have been recommended as first-line treatment for advanced EGJA patients. However, the biomarkers for predicting immunotherapy response remain controversial.

Methods

We identified stromal immune-related genes (SIRGs) by ESTIMATE from the TCGA-EGJA dataset and constructed a signature score. In addition, survival analysis was performed in both the TCGA cohort and GEO cohort. Subsequently, we explored the differences in tumor-infiltrating immune cells, immune subtypes, immune-related functions, tumor mutation burden (TMB), immune checkpoint gene expression, immunophenoscore (IPS) between the high SIRGs score and low SIRGs score grou

SUBMITTER: OuYang LY 

PROVIDER: S-EPMC9424497 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature